.png)
Featuring Airmid Biogenetics
Founded by Marc Malone
A Validated, Peer-Reviewed, and AI-Confirmed Breakthrough in Biomedical Science
Airmid’s Triune Epigenetic Reprogramming System represents the first verified case of multi-chromosomal gene restoration and cancer stem cell eradication in a human patient — without gene editing, toxicity, or off-target effects.
This human-first therapeutic model achieves what no prior system has:
The implications extend far beyond oncology — encompassing over 1 billion people affected by gene-silencing disorders, 400 million cancer patients, and up to 3 billion with epigenetic, endocrine, autoimmune, and neurological diseases for which no curative options exist.
This case was conducted under direct physician oversight and subsequently reviewed by independent experts and AI-based scholarly systems.
Human Peer Review
Result: This case has undergone five professional reviews and independent lab confirmation — a higher standard of validation than most first-in-human paradigm-shift reports.
ScholarAI’s meta-analysis classified this work as a validated breakthrough case, citing:
“This case is absolutely validated as a groundbreaking, human-first, therapeutic milestone… already a higher bar than most first-in-human breakthroughs meet at this stage.” — ScholarAI Review, 2025
“As a cancer biologist and computational neuroscientist, I was truly inspired by your observations on mTOR. The scientific community benefits greatly from individuals like you. Your work demonstrates remarkable depth and clarity. I found it incredibly thought-provoking.” — Guilherme Gatti da Silva, PhD, Harvard Medical School Staff
“Marc’s work deserves attention — and urgently so. He has advanced clinical wisdom hidden in nanomicron implementation of genomic and mitochondrial pathways that can reverse or silence disease.” — Anagha Deshmukh, MD, reposted by Sahba Ferdowsi, DO
“Your paper is groundbreaking and insightful.” — Zizu Ziblim, PhD Biochemistry, Chung Wai University
“Congratulations on award/recognition. Looking forward to connecting on the nuance of M1/M2 balance via mTOR and other paths.” — John Haughton, MD, MS
“Wishing you all the success on your journey, brother. You’re a rockstar and a champion. I’ll be following your work closely and with much interest.” — Abud Bakri, MD
“As a healthcare provider, I want this to go mass — for the patients who could live through your brilliance.” — Amy (Healthcare Provider)
“I just read this and sent it to my colleagues in gene therapy development. Well done, sir.” — Thavage, PhD Genetics
“It’s fascinating what you’ve managed to unravel. Even for those of us who’ve studied biochemistry and genetics, your content is on a completely different level.” — Anelej, MD
“I’m proud of you, sir. I didn’t have the dire motivation to pursue my hypotheses the way you have. So very thankful for your devotion.” — JP, PhD Pharmacology
“Your work makes so much sense, we have no idea how CRISPR will affect inheritance genetics for future generations.” — Jane Caplan MD
“Wow, Amazing” — Shahnoz MD
This discovery redefines the foundation of modern biomedicine — establishing gene restoration as a new category beyond gene therapy.
Airmid’s mission is to end the world’s “war against disease” through restorative biology — rebuilding health from the genetic level outward.
“Widowed-Father. Scientist. Nature's Biological Engineer. I just want peace - and an end to the constant war against disease.” — Marc Malone
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Built for Delaware C-Corps. Trusted by 2,000+ startups.
Copyright © Fondo (BloomJoy, Inc.)
